

Data + Perspectives: Clinical Investigators Discuss the Current and Future Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III VIALE-A trial evaluating azacitidine in combination with either venetoclax or placebo for patients with treatment-naïve acute myeloid leukemia (AML) not eligible for intensive therapy demonstrated which clinical outcome on the azacitidine/venetoclax arm?**
 - Improvement in complete remission rates only
 - Improvement in overall survival only
 - Improvement in complete remission rates and overall survival
 - No significant difference in complete remission rates or overall survival between the study arms
- 2. The combination of venetoclax and azacitidine is effective in which of the following patients with chemotherapy-ineligible, untreated AML?**
 - Patients with FLT3-TKD mutations only
 - Patients with IDH mutations only
 - Patients with both FLT3-TKD and IDH mutations
- 3. Which of the following drug types best describes the mechanism of action of gilteritinib?**
 - Bcl-2 inhibitor
 - IDH1/2 inhibitor
 - FLT3 inhibitor
 - JAK2 inhibitor
- 4. Which of the following drug types best describes magrolimab?**
 - Hypomethylating agent
 - Bcl-2 inhibitor
 - Anti-CD47 monoclonal antibody
 - Anti-CD20 monoclonal antibody
 - Bispecific antibody